AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
Phase 3positiveRepathaPositive
AI Analysis
Summary
Amgen announced that Repatha met its Phase 3 primary endpoint by reducing the risk of death from all causes in high-risk patients for a first heart attack or stroke, becoming the first and only PCSK9 inhibitor to demonstrate this mortality benefit in primary prevention patients.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Repatha reduced risk of death from all causes, including cardiovascular events, in high-risk primary prevention patients
Importance:8/10
Sentiment:
0.85
PCSK9 inhibitorcardiovascularmortality reductionprimary preventionPhase 3 trial
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 31, 2026 7:18 AM